Brief: Nurix Therapeutics Outlines 2024 Strategic Priorities
08/01/2024 14:01
Jan 8 (Reuters) - Nurix Therapeutics Inc NRIX.O :
* NURIX THERAPEUTICS OUTLINES 2024 STRATEGIC PRIORITIES WITH
ADVANCEMENT OF TARGETED PROTEIN MODULATION PIPELINE IN CANCER
AND AUTOIMMUNE DISEASES
* NURIX THERAPEUTICS INC - PLANS TO EXPAND THERAPEUTIC AREA
FOCUS
IN AUTOIMMUNE AND INFLAMMATORY DISEASES
* NURIX THERAPEUTICS INC - BASED ON OUR CURRENT OPERATING
PLAN
NURIX HAS CASH RUNWAY INTO SECOND HALF OF 2025
Source text for Eikon: ID:nGNX1ypS3N
Further company coverage: NRIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis